IL6 and breast carcinoma: Of note, reducing IL-6 in the TME may not only help abrogate the symptoms of CRS, but it has the potential to simultaneously limit the effect of TAMs, since TME-derived IL-6 is often implicated in the pathogenesis of many cancers due to its positive feedback loops that promote tumor growth, such as in ovarian cancer, breast cancer, and multiple myeloma (107–110).